

Yongping You

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9457018/yongping-you-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

67
papers

4,257
citations

39
h-index

65
g-index

71
ext. papers

4,952
ext. citations

5.9
avg, IF

5.23
L-index

#	Paper	IF	Citations
67	TGF- β modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT. <i>Neuro-Oncology</i> , 2021 , 23, 435-446	1	12
66	EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1-2 signaling. <i>Neuro-Oncology</i> , 2021 , 23, 611-624	1	39
65	Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p. <i>Theranostics</i> , 2021 , 11, 1763-1779	12.1	13
64	Upregulation of miR-340 Inhibits Tumor Growth and Mesenchymal Transition via Targeting c-MET in Glioblastoma. <i>Cancer Management and Research</i> , 2020 , 12, 3343-3352	3.6	1
63	DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma. <i>Molecular Cancer</i> , 2020 , 19, 28	42.1	63
62	PTEN Suppresses Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PGK1. <i>Molecular Cell</i> , 2019 , 76, 516-527.e7	17.6	55
61	Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 166	12.8	103
60	Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. <i>EBioMedicine</i> , 2019 , 42, 238-251	8.8	86
59	Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma. <i>Oncogene</i> , 2019 , 38, 2706-2721	9.2	23
58	MiR-15b/HOTAIR/p53 form a regulatory loop that affects the growth of glioma cells. <i>Journal of Cellular Biochemistry</i> , 2018 , 119, 4540-4547	4.7	24
57	miR-129-5p targets Wnt5a to block PKC/ERK/NF- κ B and JNK pathways in glioblastoma. <i>Cell Death and Disease</i> , 2018 , 9, 394	9.8	62
56	Delivery of MGMT mRNA to glioma cells by reactive astrocyte-derived exosomes confers a temozolomide resistance phenotype. <i>Cancer Letters</i> , 2018 , 433, 210-220	9.9	48
55	Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. <i>Cancer Letters</i> , 2018 , 436, 10-21	9.9	92
54	Activation of bradykinin B2 receptor induced the inflammatory responses of cytosolic phospholipase A after the early traumatic brain injury. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018 , 1864, 2957-2971	6.9	7
53	miR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomas. <i>Oncolmmunology</i> , 2018 , 7, e1510277	7.2	12
52	Genome-wide identification of epithelial-mesenchymal transition-associated microRNAs reveals novel targets for glioblastoma therapy. <i>Oncology Letters</i> , 2018 , 15, 7625-7630	2.6	9
51	Involvement of P2X Receptor in Proliferation and Migration of Human Glioma Cells. <i>BioMed Research International</i> , 2018 , 2018, 8591397	3	24

50	MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT. <i>Journal of Neuro-Oncology</i> , 2017 , 133, 59-68	4.8	23
49	Polycomb group expression signatures in the malignant progression of gliomas. <i>Oncology Letters</i> , 2017 , 13, 2583-2590	2.6	4
48	Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma. <i>Neuro-Oncology</i> , 2017 , 19, 1195-1205	1	73
47	miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas. <i>Neuro-Oncology</i> , 2017 , 19, 55-65	1	84
46	EZH2 alteration driven by microRNA-524-5p and microRNA-324-5p promotes cell proliferation and temozolomide resistance in glioma. <i>Oncotarget</i> , 2017 , 8, 96239-96248	3.3	15
45	Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. <i>Cell</i> , 2016 , 167, 1281-1295.e18	56.2	155
44	Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 1099-108	1	71
43	BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53. <i>Scientific Reports</i> , 2016 , 6, 39743	4.9	23
42	Localizing seizure-susceptible brain regions associated with low-grade gliomas using voxel-based lesion-symptom mapping. <i>Neuro-Oncology</i> , 2015 , 17, 282-8	1	80
41	PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/βcatenin signaling pathway. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2015 , 51, 1047-55	2.6	28
40	MiR-622 suppresses proliferation, invasion and migration by directly targeting activating transcription factor 2 in glioma cells. <i>Journal of Neuro-Oncology</i> , 2015 , 121, 63-72	4.8	42
39	c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma. <i>Brain</i> , 2015 , 138, 3654-72	11.2	50
38	Upregulation of miR-181s reverses mesenchymal transition by targeting KPNA4 in glioblastoma. <i>Scientific Reports</i> , 2015 , 5, 13072	4.9	51
37	NF-κB/RelA-PKM2 mediates inhibition of glycolysis by fenofibrate in glioblastoma cells. <i>Oncotarget</i> , 2015 , 6, 26119-28	3.3	36
36	MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype. <i>Oncotarget</i> , 2015 , 6, 11676-82	3.3	18
35	IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma. <i>Oncotarget</i> , 2015 , 6, 30232-8	3.3	53
34	The SIRT2 polymorphism rs10410544 and risk of Alzheimer's disease: a meta-analysis. <i>NeuroMolecular Medicine</i> , 2014 , 16, 448-56	4.6	23
33	MicroRNA-377 inhibited proliferation and invasion of human glioblastoma cells by directly targeting specificity protein 1. <i>Neuro-Oncology</i> , 2014 , 16, 1510-22	1	53

32	TPM3, a strong prognosis predictor, is involved in malignant progression through MMP family members and EMT-like activators in gliomas. <i>Tumor Biology</i> , 2014 , 35, 9053-9	2.9	15
31	MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. <i>Neuro-Oncology</i> , 2014 , 16, 1341-53	1	98
30	Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675. <i>PLoS ONE</i> , 2014 , 9, e86295	5.7	227
29	MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. <i>Oncotarget</i> , 2014 , 5, 12908-15	3.3	48
28	Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014 , 33, 9	12.8	42
27	Prevalence and clinicopathologic characteristics of the molecular subtypes in malignant glioma: a multi-institutional analysis of 941 cases. <i>PLoS ONE</i> , 2014 , 9, e94871	3.7	29
26	Genetic polymorphisms of DNA double-strand break repair pathway genes and glioma susceptibility. <i>BMC Cancer</i> , 2013 , 13, 234	4.8	37
25	Involvement of FOS-mediated miR-181b/miR-21 signalling in the progression of malignant gliomas. <i>European Journal of Cancer</i> , 2013 , 49, 3055-63	7.5	51
24	Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP- primary glioblastoma. <i>Cancer Letters</i> , 2013 , 328, 120-5	9.9	53
23	Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. <i>Cancer</i> , 2013 , 119, 814-24	6.4	74
22	MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas. <i>Journal of Neuro-Oncology</i> , 2012 , 106, 217-24	4.8	32
21	Functional differences of miR-125b on the invasion of primary glioblastoma CD133-negative cells and CD133-positive cells. <i>NeuroMolecular Medicine</i> , 2012 , 14, 303-16	4.6	38
20	High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. <i>Journal of Translational Medicine</i> , 2012 , 10, 119	8.5	103
19	New insights into the roles of ncRNA in the STAT3 pathway. <i>Future Oncology</i> , 2012 , 8, 723-30	3.6	28
18	MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. <i>International Journal of Oncology</i> , 2012 , 40, 119-29	4.4	58
17	miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. <i>Neuro-Oncology</i> , 2012 , 14, 712-9	1	144
16	Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. <i>Neuro-Oncology</i> , 2012 , 14, 1432-40	1	133
15	Upregulation of miR-196b confers a poor prognosis in glioblastoma patients via inducing a proliferative phenotype. <i>PLoS ONE</i> , 2012 , 7, e38096	3.7	48

14	Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avβ/PI3K/AKT/eNOS/NO signaling pathway in glioma cells. <i>European Journal of Cell Biology</i> , 2011 , 90, 642-8	6.1	74
13	MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10. <i>Brain Research</i> , 2011 , 1389, 9-18	3.7	148
12	Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. <i>Brain Research</i> , 2011 , 1411, 108-15	3.7	111
11	Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. <i>Laboratory Investigation</i> , 2010 , 90, 144-55	5.9	293
10	PUMA is a novel target of miR-221/222 in human epithelial cancers. <i>International Journal of Oncology</i> , 2010 , 37, 1621-6	4.4	63
9	MiR-181b suppresses proliferation of and reduces chemoresistance to temozolomide in U87 glioma stem cells. <i>Journal of Biomedical Research</i> , 2010 , 24, 436-43	1.5	34
8	miR-221/222 promote malignant progression of glioma through activation of the Akt pathway. <i>International Journal of Oncology</i> , 2010 , 36, 913-20	4.4	72
7	AKT2 expression is associated with glioma malignant progression and required for cell survival and invasion. <i>Oncology Reports</i> , 2010 , 24, 65-72	3.5	29
6	Reduction of miR-21 induces glioma cell apoptosis via activating caspase 9 and 3. <i>Oncology Reports</i> , 2010 , 24, 195-201	3.5	75
5	MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation. <i>Brain Research</i> , 2010 , 1312, 120-6	3.7	111
4	Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. <i>International Journal of Oncology</i> , 2009 , 34, 1653-60	1	56
3	hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. <i>Brain Research</i> , 2008 , 1236, 185-93	3.7	363
2	Glioma cells enhance endothelial progenitor cell angiogenesis via VEGFR-2, not VEGFR-1. <i>Oncology Reports</i> , 2008 , 20, 1457-63	3.5	6
1	Antisense telomerase RNA inhibits the growth of human glioma cells in vitro and in vivo. <i>International Journal of Oncology</i> , 2006 , 28, 1225-32	1	3